Aspects of liver toxicity (described for ulipristal acetate [67] but not for mifepristone) as well as the impact of long term treatment of antiprogestins on the endometrium and immune function will need to be assessed prior to considering selective progesterone receptor modulators in a breast and ovarian cancer-preventive setting. This evidence concerns the gene PGR and ovarian cancer.